Blueprint Medicines Corp. (NASDAQ:BPMC) shares dropped 2.4% during mid-day trading on Monday after an insider sold shares in the company. The company traded as low as $28.20 and last traded at $29.04, with a volume of 238,487 shares. The stock had previously closed at $29.75.

Specifically, Director Daniel Lynch sold 21,800 shares of the company’s stock in a transaction dated Thursday, October 13th. The stock was sold at an average price of $30.02, for a total transaction of $654,436.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jeffrey W. Albers sold 17,000 shares of the company’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $22.86, for a total value of $388,620.00. Following the sale, the chief executive officer now owns 76,494 shares in the company, valued at approximately $1,748,652.84. The disclosure for this sale can be found here. Corporate insiders own 3.93% of the company’s stock.

BPMC has been the topic of several analyst reports. Zacks Investment Research upgraded Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a report on Thursday, August 11th. Cowen and Company reissued a “buy” rating on shares of Blueprint Medicines Corp. in a research report on Tuesday, August 9th. Canaccord Genuity assumed coverage on Blueprint Medicines Corp. in a research report on Friday, August 5th. They set a “buy” rating and a $26.00 price target on the stock. TheStreet raised Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a research report on Friday, July 29th. Finally, Wedbush reissued an “outperform” rating and set a $41.00 price target on shares of Blueprint Medicines Corp. in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $30.00.

The company’s 50-day moving average is $28.15 and its 200-day moving average is $22.05. The stock’s market cap is $786.86 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last issued its earnings results on Tuesday, August 9th. The company reported ($0.70) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.73) by $0.03. The company earned $7.07 million during the quarter, compared to the consensus estimate of $4.41 million. Blueprint Medicines Corp. had a negative return on equity of 46.01% and a negative net margin of 284.85%. The firm’s revenue for the quarter was up 163.0% compared to the same quarter last year. During the same period last year, the business posted ($0.81) EPS. On average, analysts expect that Blueprint Medicines Corp. will post ($3.05) EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the stock. BVF Inc. IL increased its stake in shares of Blueprint Medicines Corp. by 15.9% in the first quarter. BVF Inc. IL now owns 2,640,251 shares of the company’s stock valued at $47,657,000 after buying an additional 361,792 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of Blueprint Medicines Corp. by 46.8% in the second quarter. BlackRock Fund Advisors now owns 871,793 shares of the company’s stock valued at $17,654,000 after buying an additional 277,781 shares during the last quarter. State Street Corp boosted its position in shares of Blueprint Medicines Corp. by 142.4% in the second quarter. State Street Corp now owns 325,396 shares of the company’s stock valued at $6,587,000 after buying an additional 191,138 shares during the last quarter. BlackRock Institutional Trust Company N.A. boosted its position in shares of Blueprint Medicines Corp. by 41.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 328,630 shares of the company’s stock valued at $6,655,000 after buying an additional 96,761 shares during the last quarter. Finally, Lord Abbett & CO. LLC boosted its position in shares of Blueprint Medicines Corp. by 65.9% in the second quarter. Lord Abbett & CO. LLC now owns 210,581 shares of the company’s stock valued at $4,264,000 after buying an additional 83,677 shares during the last quarter. Institutional investors own 73.65% of the company’s stock.

Blueprint Medicines Corp. Company Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

5 Day Chart for NASDAQ:BPMC

Receive News & Stock Ratings for Blueprint Medicines Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corp. and related stocks with our FREE daily email newsletter.